Agoracom Blog Home

Archive for the ‘Applied BioSciences’ Category

Applied BioSciences $APPB: Innovative CBD System Balancing $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM-Eric at 2:31 PM on Monday, January 27th, 2020

SPONSOR: Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals; targeting the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas. Click Here for More Info

https://cdn.chiroeco.com/wp-content/uploads/2020/01/i1-20-digital4-1024x576.jpg
An endocannabinoid deficiency can result in a host of patient afflictions, but this innovative CBD balancing strategy can help patients

All cannabidiol (CBD) is not created equal in clinical practice in terms of implementation. The most frustrating thing for clinicians and also for patients is when an intended protocol doesn’t work. As I discuss later under the “With treatment, start low” section of this article, there are ways to use CBD most effectively.

You probably weren’t taught this in medical school, but CBD works on the endocannabinoid system (ECS). The ECS contains CB1 and CB2 receptors, in addition to other receptors that are activated by the naturally occurring endocannabinoids made in our bodies, called anandamide and 2-AG. We all have CB1 or CB2 receptors within our body — if you have a cat or dog, they have these receptors too. All mammals do. How could it be that we did not even know of the predominance of the ECS until 1992?

What the endocannabinoid system can do

Patients coming in worn out can be a sign of endocannabinoid deficiency and the inability to support their pathways optimally, much like adrenal fatigue. Phytocannabinoids like CBD obtained from hemp products can act on the same receptors as endocannabinoids made in the body. CBD receptors, much like opioid receptors, control pain, but via a different mechanism.

Patients arrive at our clinical practices fatigued, anxious, in pain, inflamed, and lots reach a point of adrenal burnout, adrenal fatigue. Indeed, that is often the case because they are suffering from an endocannabinoid deficiency. We see people who have low adrenal function at noon, and in the evening, they are tired, dragging, eat lunch, get a little spike, and then they start free falling again. They’re flat-lining. How is it that we wake up each morning anticipating with trepidation and run with go, go, go pace and finish the day glad to have survived another day? Life is meant for more than that; it is time to shift our goals from merely surviving to thriving mode!

Researchers observed approximately six years ago that people were more anxious and depressed in the middle of the summer than ever before, a new phenomenon. This goes against what we previously believed, that depression spiked mostly in the holiday season and Thanksgiving and after the winter solstice. But now we’re seeing people are worn out even in summer. Indeed, the endocannabinoid system plays a role here.

Anandamide is one of our endocannabinoids. When it becomes lower, patients are more anxious. There is less healing of the brain, less neurogenesis, and the hypothalamic-pituitary axis is triggered, causing a whole cascade of events to occur. What we now know is that the endocannabinoid system naturally, or with the use of CBD, alters our microbiome in our gut, beneficially affecting the gut-brain axis. The GI tract is the site of many receptors. We make about 70% of our serotonin, the happy-brain chemical, in the GI tract. About 70-80% of our immune system is in our GI tract, so is it any surprise that we have CB1, CB2 regulatory pathways in our GI tract that work via the endocannabinoid system to control inflammation? These same pathways can be regulated using an innovative CBD strategy.

Migraines and the endocannabinoid system

With endocannabinoid deficiency symptoms patients can get migraines. We thought migraines were just triggered by tyramine-rich foods, such as cheese, fermented foods, and salami and other such foods; along with other triggers as well.

However, the endocannabinoid pathway is designed to control pain and inflammation and also regulate the immune system to a large degree. I have found in my clinical practice that innovative CBD strategies can be useful in supporting the health of migraine sufferers.

Treat the brain, treat the pain

The body is designed with innate intelligence to sustain optimal performance. People ask, “Well, how is CBD metabolized?” It’s primarily metabolized through the liver, and as a result, it goes through the cytochrome 450 and other pathways.
Wellness is ultimately about homeostasis. We all know the term entropy, the tendency for the universe to move toward chaos. But our body exerts a phenomenal amount of energy to maintain order and wellness. However, if the endocannabinoid system becomes deficient, this will adversely affect wellness. This endocannabinoid deficiency, in turn, affects the microbiome, contributing to a less healthy endocannabinoidome.

CBD can conserve anandamide that is made by the body, and CBD can support anandamide conservation in an attempt to bring the body back into homeostasis. The endocannabinoid system supports brain health. By treating the brain, it addresses the pain, because if we didn’t have a brain, we wouldn’t feel the pain from a perception perspective.

Anxiety also is a biochemical process. It’s real. A lot of people say, “It’s all in my head.” No, stress is real because it’s a physiological effect. There is biochemistry involved in anxiety. We want to use innovative CBD strategies to support calming pathways and bring peace and harmony into the brain.

Endocannabinoid deficiency issues

If a patient has brain inflammation, neuroplasticity is not going to be as healthy or robust. And the fact is, on a typical day, we lose about 86,400 brain cells. CBD is an anti-inflammatory application. And from a neuropathic perspective, activation of cannabinoid receptors is essential. I’ve looked at research involving the endocannabinoid system relative to cancer medications and so forth. Not being an oncologist, I am not suggesting this is a treatment for cancer, but there are pain, stress and immune challenges that often need to be associated with this disease state, so visiting with one’s provider in this arena is vital.

We can start manifesting symptoms of migraines, fatigue, irritable bowel, whatever it might be, as a result of being subpar, insufficient or deficient of endocannabinoids. An endocannabinoid deficiency manifests itself as simply that the body has gotten worn down, much like low adrenal function, often called adrenal fatigue. So we need to support that pathway to bring it back on track like we would any other functional biochemistry, which our body is designed to do. And since we’re designed to make endocannabinoids, we need to bring those levels back up to par.

With treatment, start low

The goal is to start low and go slow, as a little bit can go a long way for many patients. More is not always better, as each person responds differently based on genetics, biochemistry and individual need.

Just like if you’re performing an adjustment, a little bit of a movement might get the job done. Work with gentle modulation of the endocannabinoid system. You’re working within the innate ability of the body.

Fifteen to 25 milligrams per day is what I start my patients on. In a week or two, if I need to move them up to 25 mg two to three times a day, I will. Once again, if a little bit gets the job done, why more? It is of paramount importance to respect the innate delicate balance physiology of the body. Some patients will need much higher doses because of their endocannabinoid insufficiency or potential genetic polymorphisms. You’re going to encounter genetic polymorphisms, or what I termed mutations of the CBD receptors and the CBD pathway.

I never go to high-milligram doses, especially on patients taking pharmaceutical drugs, without working with their pharmacists, because CBD can affect similar liver detoxification, as well as other biochemical pathways of how drugs are metabolized, much like grapefruit juice, can impact many of the same medications. We want to also support those drug-metabolizing pathways with diet and lifestyle.

CBD, when dosed properly, can positively supplement a health-promoting diet and lifestyle. It’s not a substitute for these things. So, we want to ensure we’re taking steps to support the body at a foundational level. Additionally, we always want to ensure the THC levels in the CBD you are using are less than 0.3%, or that the CBD contains no THC, when targeting hemp-derived CBD.

We all get broken or get older

Endocannabinoid deficiency is associated with low cortisol, stress and adrenal fatigue. We’re all getting older. Our mitochondria are wearing down. Our nitric oxide levels aren’t as robust as they used to be, and we need support at a fundamental level. In regards to the 65 potential molecular targets that are currently known for CBD, there is a lot of untapped potential here relative to stress and aging. Innovative CBD use is a new area; it can be a scary area, but remember, our bodies have been producing endocannabinoids for millennia. All we’re doing is supporting a natural pathway.

source: https://www.chiroeco.com/innovative-cbd/

Applied BioSciences $APPB: How CBD and The Endocannabinoid System Work Together $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM-Eric at 10:43 AM on Tuesday, January 21st, 2020

SPONSOR: Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals; targeting the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas. Click Here for More Info

Before we can take a look at how CBD and the Endocannabinoid System (ECS) work together, we must first understand the ECS.

The human body has an endocannabinoid system, just like it has an endocrine system and a number of other systems that work together to function. The ECS is what makes it possible for CBD, THC, and other cannabinoids in the marijuana and hemp plants – there are hundreds – to work on the body.

In 1988, researchers found the first cannabinoid receptor in the brain of a rat. They found that the receptors interacted exclusively with receptors found in the cannabis compound, THC. That’s the cannabinoid everyone’s most familiar with because it is the compound responsible for the stoned feeling associated with marijuana consumption.

The researchers discovered that the receptors were concentrated in areas of the brain that plays a role in a number of physiological and mental processes, including emotion, motor coordination, high cognition, and memory.

In 1993, another cannabinoid receptor was discovered. It was found distributed throughout the immune system and peripheral body tissues. It displayed the same reaction to THC as the first receptor.

In 1995, the two receptors, that had been named CB1 and CB2, were found not only in rats, but in humans, and thousands of other species.

As technology advanced, researchers further explored the relationship between cannabinoid receptors in the body, known as endocannabinoids, and the cannabinoid receptors in cannabis compounds such as CBD oil and THC – known as phytocannabinoids.

What is the Purpose of Endocannabinoids?

The endocannabinoid system was discovered in the late 1990s, and since then, researchers have learned a great deal about the relationship between phytocannabinoids and endocannabinoids.

Because we know endocannabinoids are present throughout the body in numerous functions, researchers believe they may help maintain these functions.

Imagine for a moment the body is a machine, where each system works together to keep the machine moving and working. The immune system, for instance, would be the filtration system. The brain would be the motherboard, and the endocannabinoids help to maintain the systems.

CB1 receptors are concentrated in the brain and central nervous system. Your central nervous system is responsible for maintaining all the core functions such as pain perception, stress response, motor activity, and memory.

CB receptors are located in many of the peripheral organs in the body, suggesting they are core components of the cardiovascular system, the immune system, and the muscular system.

Why Phytocannabinoids Matter

Machines, whether due to natural aging, poor maintenance, or damage, may malfunction. And like those machines, our body’s systems and parts can break down and malfunction, causing issues within the entire body and any number of health conditions.

Endocannabinoids help maintains your body’s health, but if the level of endocannabinoids in the body declines, in theory, they’d only be able to maintain the body’s current state of health. As such, there likely wouldn’t be enough to stop it from declining any further. Over time, the health level decreases gradually, and in the process, creates bigger health problems.

That’s where phytocannabinoids, such as CBD come into play.

How CBD Works in the Body

Research has taught us that when CBD bonds with either the CB1 or CB2 receptors in the body, it either alters or improves that receptor’s capabilities, which improves that receptor’s functionality.

If the body is suffering a cannabinoid deficiency, adding them to your body, for example, by using CBD gummies for stress, helps to equalize the deficiency. Right now, studies point to the theory that cannabinoids are a finite resource. The deficiency of cannabinoids may cause a number of health issues, including irritability and headaches.

Essentially, using CBD enables us to boost our ECS. Because it bonds with our CB1 and CBD2 receptors, CBD helps the body maintain vital health functions and helps restore balance, also known as homeostasis, within the body. This is the reason it has so many health benefits.

CBD Benefits

When you really think about it, the majority of health problems can be traced back to an imbalance somewhere in the body.

In a healthy body, all is as it should be, and the body is balanced. In an unhealthy body, however, there is either too much or too little of something (or multiple somethings). This creates a disruption in homeostasis and presents a variety of symptoms, which vary depending on the nature of the imbalance.

Think about the various health conditions that are a result of imbalance, and how CBD can help improve these conditions by restoring balance:

  • Inflammation: This is often characterized by a part of your body swelling, and sometimes becoming hot. It can be incredibly painful, and range from mild, to severe enough to incapacitate someone. Inflammation in the body is linked to autoimmune disorders, arthritis, and bacterial infections. CBD can be helpful to treat inflammation because it suppresses the inflammatory pathways and responses, stimulates regulatory cell production, and manages our pain perception.
  • Seizures: Seizures are the result of erratic electrical impulses in the brain, which causes violent shaking in the body. In patients suffering from two severe forms of epilepsy known as Lennox Gaustat Syndrome and Dravet Syndrome, CBD reduces the number of seizures because it slows down the excitatory nerve activity and subdues the brain’s reaction to the intense signals that cause the overload.
  • Anxiety and stress: Most people experience stress and anxiety as a response to situations that are perceived as unwanted, dangerous, or risky. Hormonal imbalance or excessive messages in the brain boosts cortisol levels and causes you to feel stress. CBD combats this by regulating how your brain responds to stress signals and maintaining normal cortisol levels.

These, of course, are only a few examples of the studies supporting CBD as an effective treatment.

There are hundreds of other studies supporting its use to treat a wide number of other conditions, such as addiction, acne, depression, schizophrenia and more. It’s all because of our ECS, and the fact that our bodies contain parts linked directly to the cannabis plant is pretty amazing.

SOURCE: https://www.latintimes.com/how-cbd-and-endocannabinoid-system-work-together-454648

Terpenoids And Cannabinoids – What’s The Difference? SPONSOR: Applied BioSciences $APPB $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM-Eric at 12:00 PM on Monday, January 6th, 2020

SPONSOR: Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas Click Here for More Info

If you have been studying cannabis products in depth to find out that one full-spectrum CBD oil that would suit all your needs then you’d have come across the word terpenes. But what are these terpenes, or as others refer them, terpenoids?

Of course, if you are looking to buy CBD, you would be aware of what cannabinoids are. these are compounds found in the cannabis plants, hemp and marijuana. So now you have two terms cannabinoids and terpenoids – but what’s the difference between the two? let’s take a look at this below:

Cannabinoids

Cannabinoids like cannabidiol and tetrahydrocannabinol have therapeutic properties. They interact with the natural endocannabinoid system in your body. What they basically do is that they control the functionality of cells – this means they manage cell signaling.

Cannabinoids regulate the receiving, processing, and sending of messages between cells. A cannabinoid like CBD can interact with cannabinoid receptors in the ECS and regulate your mood, anxiety, inflammatory response, and much more.

While THC and CBD are the most popular cannabinoids that have studies supporting their effects, there are hundreds of other cannabinoids too. These include CBG and CBN among others. All cannabinoids come with distinct features.

Terpenes

Terpenes or terpenoids are aromatic molecules not only found in cannabis but in several other plants as well. These as well have therapeutic properties. They are found in fruits as well. Terpenes in the lavender flower are responsible for its unique aroma and soothing properties.

Terpenes also found in citrus fruits and berries too. One terpene that exists in both cannabis as well as a fruit, mango, is myrcene. The aroma of weed that many people appreciate comes from this very terpene. Inside plants, terpenes play a very important role. They protect against the attack of pests, bacteria and other external agents. The amount and type of terpenes in cannabis plants varies from one strain to another.

The Entourage Effect

Experts recommend you to go for a full-spectrum CBD formula because it contains cannabinoids as well as terpenes. Cannabinoids and terpenoids work together to provide better benefits. They have an entourage effect together which enables you to get better result sooner. This is because like cannabinoids, terpenes also have health profiting qualities.

For instance, some terpenes have an anti-inflammatory nature while others are great for stress relief. As you may already be aware, CBD also provides these benefits. Of course, when in combination with other compounds that have similar properties benefits that you drive are more.

Verdict

Cannabinoids and terpenes are compounds found in the cannabis plant. Both have therapeutic properties but are different. Terpenes are aromatic molecules responsible for the flavor of a plant and fragrance. Cannabinoids interact with the ECS of the body. Together they work even better which is why full-spectrum CBD is revered more than CBD isolate.

SOURCE: https://prospercbdnews.com/Terpenoids+And+Cannabinoids+-+What%E2%80%99s+The+Difference%3F

Applied BioSciences $APPB Subsidiary, Trace Analytics, Receives Extension of Contract of Services from Washington State Department of Agriculture $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM-Eric at 8:37 AM on Wednesday, December 18th, 2019
  • Trace Analytics Inc. is a leading scalable analytics cannabis/cannabinoid laboratory poised to meet the demands for mandated regulatory cannabis/cannabinoid testing
  • WSDA contracted Trace Analytics for the purpose of doing cannabinoid profiling for the State’s industrial hemp program to ensure the percentages of certain cannabinoids are below Federal limits

Applied BioSciences Corp. (OTCQB:APPB) (“Applied” or the “Company”), today announced that the Washington State Department of Agriculture (WSDA) has extended its contract for services with Applied’s majority owned subsidiary, Trace Analytics Inc. (“Trace”).

The WSDA contracted Trace beginning in July 2019 for the testing of Industrial Hemp samples and percentage testing for delta 9-tetrahydrocannabidiol (THC) and delta 9-tetrahydocannabinolic acid (THC-A) to ensure the percentages of certain cannabinoids are below Federal limits.

“We are grateful for our relationship with the WSDA and are pleased to continue cannabinoid profiling for the WSDA’s Industrial Hemp program. The testing and reporting of results that we have conducted to date have demonstrated the quality of our analytics and our dedication to ensuring compliance with Federal limits,” stated Jason Zitzer, Chief Operating Officer of Trace Analytics. “We provide expert consulting services to government entities at all levels around the world and are appreciative to WSDA to have been selected as the sole lab to conduct their testing. This contract extension provides another opportunity toward establishing a higher quality for cannabis and hemp testing.”

Trace Analytics Inc. is a leading cannabis science and technology company with significant footprints in lab testing, research and development and licensing. Trace Analytics was started by a group of scientists who specialized in analytical chemistry, genetics and molecular biology, focused on ensuring compliance with public safety standards and end user safety. Trace Analytics is in the process of expanding throughout the United States, and globally with the goal of helping the rest of the world adopt “best practices” in cannabis and hemp testing. The Company also provides expert consulting services to legislators and regulators in many countries, states and municipalities around the world.

Based on Applied BioSciences’ stated strategic corporate shift to focus on its BioPharma division and the development and commercialization of novel therapeutics that target the endocannabinoid system (ECS), the Company is currently evaluating a strategic transaction of Trace Analytics. Applied is currently in late-stage discussions and expects to close the transaction by year end.

About Applied BioSciences Corp.

Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas. We also deliver high-quality consumer and OTC THC-free CBD products that promote overall health and wellbeing as well as state-of-the-art testing and analytics capabilities to our customers. For more information, visit appliedbiocorp.com and connect with the Company on Twitter, Facebook and LinkedIn.

Applied BioSciences $APPB: Announces Strategic Shift to Fully Focus on BioPharma Division $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM-Eric at 8:46 AM on Wednesday, December 4th, 2019
  • BioPharma division is focused on the development and commercialization of novel therapeutics that target the endocannabinoid system (ECS)
  • BioPharma Division focus unlocks opportunities for non-dilutive capital to fund high-value pipeline
  • Company seeking to spin-off Applied Products division comprised of a portfolio of consumer, animal health, women’s health and sports medicine CBD products
  • Majority owned subsidiary, Trace Analytics, in late-stage discussions for a strategic transaction, expected close to year end 

Applied BioSciences Corp. (OTCQB:APPB) (“Applied” or the “Company”), today announced its strategic corporate shift to fully focus all initiatives and resources on its BioPharma division and the development of science-driven biopharmaceuticals that target the endocannabinoid system.

Through its Applied Products division, the Company currently develops multiple brands offering high quality health and wellness CBD products that conform to the highest regulatory standards and markets through established channels in the US. To date, the Applied Products business unit has seen robust year-over-year increase in top-line revenue. At this time and with the understanding that to be successful in the lucrative yet dynamic and very competitive consumer CBD space would require additional resources and capital allocations, the Applied Board has made the strategic decision to allocate all resources moving forward to the BioPharma business unit.

“After careful consideration, the Board has made the strategic decision that it is in the best interest of the Company and our shareholders, to spin off our consumer-facing CBD business, Applied Products. We believe that this streamlined corporate development pathway will unlock opportunities for non-dilutive capital to expand and advance our pipeline of novel therapeutics addressing areas of high value indications where there remain significant unmet needs,” commented Dr. Raymond Urbanski, Chief Executive Officer of Applied. “Both our Trace Analytics and Products business units represent promising investment opportunities and we are confident that we will be able to identify the right partners to give each unit the proper share of voice in this competitive field.”

“Moving forward we see great potential in our growing BioPharma pipeline. We look forward to continue building momentum and establishing Applied BioPharma as a leader in the development and commercialization of innovative therapeutics that target the endocannabinoid system,” added Dr. Urbanski.

To date, the Applied BioPharma division has developed partnerships with leading academic and research institutions and has exclusively licensed patented, synthetically derived small molecule candidates which target the endocannabinoid (ECS) G-protein coupled receptors (GPCRs) e.g., the cannabinoid receptor 1 and cannabinoid receptor 2, for the treatment of metabolic diseases (type 2 diabetes, obesity, fatty liver disease) and inflammation (pulmonary inflammation, optic nerve inflammation following traumatic brain injury and ischemic/reperfusion injury such as acute kidney injury post-transplant and acute myocardial infarction (heart attack).

The Company’s growing pipeline is comprised of selective CB1 and CB2 agonist, inverse agonist and antagonists utilizing multiple scaffolds and state-of-the-art medicinal chemistry across several academic centers and institutions. Applied expects to advance the first of its preclinical programs into open INDs throughout 2020 and its lead clinical program into a Phase 1 study in early to mid-2020.

The Company is actively advancing and seeking additional in-license opportunities with the goal of developing an industry-leading pipeline of endocannabinoid system-targeted drug candidates that address significant unmet needs across a wide range of therapeutic areas.

About Applied BioSciences Corp.

Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas. We also deliver high-quality consumer and OTC THC-free CBD products that promote overall health and wellbeing as well as state-of-the-art testing and analytics capabilities to our customers. For more information, visit appliedbiocorp.com and connect with the Company on Twitter, Facebook and LinkedIn.

Applied BioSciences $APPB – WHO Report Finds No Public Health Risks Or Abuse Potential For CBD $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM-Eric at 3:57 PM on Wednesday, November 27th, 2019

SPONSOR: Applied Biosciences Corp. is a vertically integrated company focused on the development of science-driven cannabinoid therapeutics and biopharmaceuticals, as well as state-of-the-art testing and analytics. As a leading company in the CBD, Pet and Health and Wellness space, the company is currently shipping to the majority of US states as well as to 5 International countries. Click Here for More Info

A World Health Organization (WHO) report has found no adverse health outcomes but rather several medical applications for cannabidiol, a.k.a. CBD, despite U.S. federal policy on this cannabinoid chemical.

According to a preliminary WHO report published last month, naturally occurring CBD is safe and well tolerated in humans (and animals), and is not associated with any negative public health effects [PDF].

Experts further stated that CBD, a non-psychoactive chemical found in cannabis, does not induce physical dependence and is “not associated with abuse potential.” The WHO also wrote that, unlike THC, people aren’t getting high off of CBD, either.

“To date, there is no evidence of recreational use of CBD or any public health related problems associated with the use of pure CBD,” they wrote. In fact, evidence suggests that CBD mitigates the effects of THC (whether joyous or panicky), according to this and other reports.

The authors pointed out that research has officially confirmed some positive effects of the chemical, however.

The WHO team determined that CBD has “been demonstrated as an effective treatment for epilepsy” in adults, children, and even animals, and that there’s “preliminary evidence” that CBD could be useful in treating  Alzheimer’s disease, cancer, psychosis, Parkinson’s disease, and other serious conditions.

In acknowledgement of these kinds of discoveries in recent years, the report continued, “Several countries have modified their national controls to accommodate CBD as a medicinal product.” 

But the U.S., the report noted, isn’t one of them. As a cannabis component, CBD remains classified as a Schedule I controlled substance, meaning it has a “high potential for abuse” in the federal government’s view. Nevertheless, the “unsanctioned medical use” of CBD is fairly common, experts found.

For many CBD users in the U.S., the substance’s mostly unsanctioned and illegal state creates problems, especially as a wave of online (mostly hemp) and store-bought CBD oils and extracts have allowed patients to take the treatment process–and the risks involved in buying unregulated medicine–into their own hands and homes.

While CBD itself is safe and found to be helpful for many users, industry experts have warned that not all cannabis extracts are created equally, purely, or with the same methods of extraction.

And while reports of negative reactions to pure CBD are very few and far between, researchers are able to say that the cannabinoid wouldn’t be to blame alone. “Reported adverse effects may be as a result of drug-drug interactions between CBD and patients’ existing medications,” they noted.

As the cannabis reform nonprofit NORML reported, the WHO is currently considering changing CBD’s place in its own drug scheduling code. In September, NORML submitted written testimony to the U.S. Food and Drug Administration (FDA) opposing the enactment of in

The FDA, which has repeatedly declined to update its position on cannabis products despite a large and ever-growing body of evidence on the subject, is one of a number of agencies that will be advising the WHO in its final review of CBD.

Perhaps this time around the FDA will listen, and learn something.

The report was presented by the WHO’s Expert Committee on Drug Dependence, and drafted under the responsibility of the WHO Secretariat, Department of Essential Medicines and Health Products, Teams of Innovation, Access and Use and Policy, Governance and Knowledge.

https://www.forbes.com/sites/janetwburns/2018/03/18/who-report-finds-no-public-health-risks-abuse-potential-for-cbd/#52c681102347

Applied BioSciences $APPB – Reports Second Quarter Fiscal Year 2020 Financial Results and Outlines Corporate Strategy $CGRW $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca

Posted by AGORACOM-Eric at 8:45 AM on Friday, November 15th, 2019
  • Successfully building BioPharma pipeline in high-value indications
  • Company plans to advance IND-cleared program into a Phase 1 study in a metabolic disease indication in early 2020
  • Strategic corporate shift to fully focus on BioPharma Division unlocks opportunities for non-dilutive capital to fund pipeline

Applied BioSciences Corp. (OTCQB:APPB) (“Applied” or the “Company”), today announced its financial results for the second quarter Fiscal Year 2020 ended September 30, 2019. The Company also provided an update on its corporate and clinical progress.

“We continue to push forward on all fronts as we work to establish Applied as a leader in the development and commercialization of novel, science-driven, synthetic endocannabinoid therapeutics / biopharmaceuticals and impact areas of significant unmet need,” commented Dr. Raymond Urbanski, Chief Executive Officer of Applied. “Over the course of the past quarter, we have made notable strides on the corporate and clinical front and remain diligent in working to drive value for all stakeholders.”

“We continued to build out our BioPharma division and have established a Scientific Advisory Board of leading experts in the endocannabinoid space. We were pleased to have welcomed our inaugural members Judith Korner, M.D. and Patricia Reggio, Ph.D., who will play an integral role as we look to optimize our therapeutic pipeline and look to make additional appointments in the near term to help drive this business unit forward. Additionally, we have continued to execute on our robust business development initiatives and remain in late-stage discussions to in-license our product candidates that we believe have the potential to address a number of areas with significant unmet need. In tandem, we continue to remain opportunistic in accessing the necessary non-dilutive funding and capital through strategic investments from which we believe will provide us with the foundation and momentum to move forward.”

Applied BioPharma: developing science-driven synthetic cannabinoid therapeutics that satisfy unmet medical needs and continue to drive innovation in the endocannabinoid space.

The Applied BioPharma division is focused on the development and commercialization of novel therapeutics that target the endocannabinoid system (ECS).

Applied Biopharma has to date developed partnerships with leading academic and research institutions and has exclusively licensed patented, synthetically derived small molecule candidates which target the ECS G-protein coupled receptors (GPCRs) e.g., the cannabinoid receptor 1 and cannabinoid receptor 2, for the treatment of metabolic diseases (type 2 diabetes, obesity, fatty liver disease) and inflammation (pulmonary inflammation, optic nerve inflammation following traumatic brain injury and ischemic/reperfusion injury such as acute kidney injury post-transplant and acute myocardial infarction (heart attack).

The Company’s growing pipeline is comprised of selective CB1 and CB2 agonist, inverse agonist and antagonists utilizing multiple scaffolds and state-of-the-art medicinal chemistry across several academic centers and institutions.

  • Applied expects to advance the first of its preclinical programs into open INDs in 2020.
    • ABP-1902, its lead CB2 agonist, intended for mitigating the deleterious effects of ischemic-reperfusion injury.
    • ABP-1901, its lead CB2 inverse agonist, which has demonstrated effectiveness in limiting or reversing damage due to neuroinflammation.
  • Applied expects to advance the first of its clinical programs into a Phase 1 study in early to mid-2020.

The Company is actively advancing and seeking additional in-license opportunities with the goal of developing an industry-leading pipeline of endocannabinoid system-targeted drug candidates that address significant unmet needs across a wide range of therapeutic areas.

Applied Products: portfolio of consumer, animal health, women’s health and sports medicine of hemp-derived, THC-free, pharmaceutical grade CBD isolates and distribution products, all of which ship to the majority of U.S., as well as to multiple non-U.S. countries.

The Applied Products business unit is focused on maximizing top-line revenue through selective investments in product lines and marketing campaigns (increase share-of-voice), continually reevaluating the endocannabinoid Health & Wellness environment for opportunities and developing and implementing a nutraceutical strategy.

Applied Products has seen a modest year-over-year increase in top line revenue. At this time the Board, with the understanding that to be successful in the lucrative yet dynamic and very competitive consumer CBD space would require significant resource and capital allocations, is evaluating various strategic options for this business unit.

Trace Analytics, Inc: Applied’s majority owned subsidiary scalable analytics cannabis/cannabinoid laboratory poised to meet the demands for mandated regulatory cannabis/cannabinoid testing.

In July 2019, Trace Analytics was contracted for services with the Washington State Department of Agriculture (WSDA). This contract includes testing Industrial Hemp samples and include percentage testing for post-decarboxylation delta 9-tetrahydrocannabidiol (THC) and delta 9-tetrahydocannabinolic acid (THC-A) to ensure the percentages of certain cannabinoids are below Federal limits.

Applied is currently in late-stage discussions for a strategic transaction, expected to close by year end.

Upcoming Milestones Expected to Drive Value

  • Finalize the in-licensing of product candidates to build pipeline for the Applied BioPharma division.
  • Closing on the sale of Trace Analytics leading to the infusion of non-dilutive capital into the company.
  • Finalize and execute on the strategic options for Applied Products.
  • Successfully execute overall strategy of the Company and business development efforts.
  • Engage with key stakeholders in the investment community and execute on the robust effort to raise awareness of the Company.
  • Uplist to a National Exchange.

Summary of Financial Results for Second Quarter FY2020 Ended September 30, 2019

For the quarter ended September 30, 2019, the Company reported net loss of approximately $777,746 or net loss per diluted share of $0.06, compared to a net loss of approximately $110,423 or a net loss per diluted share of $0.01, for the quarter ended September 30, 2018.

The Company reported revenues from Applied BioSciences’ CBD product lines was $169,654 and $59,400 during the six months ended September 30, 2019 and 2018, respectively. The increase reflects higher sales across all of the Company’s CBD brand product lines, most notably in its topical products, combined with expansion into sales of bulk hemp seed and raw CBD. Service revenue resulting from the Company’s lab testing is attributed solely to the acquisition of Trace Analytics in January 2019, and totaled $286,077 for the six months ended September 30, 2019.

General and administrative expenses increased $519,140 to $707,192 for the three months ended September 30, 2019 as compared to $188,052 for the three months ended September 30, 2018. The increase was mainly attributable to the acquisition of Trace Analytics and addition of our Applied BioPharma subsidiary, with general and administrative expenses for the remainder of the Company.

The Company ended the quarter with $73,412 in cash and cash equivalents. The Company is actively evaluating opportunities to fund continued growth in its products and services revenue along with planned business development activities for Applied BioPharma and anticipates closing a financing by the end of first quarter Fiscal Year 2020.

About Applied BioSciences Corp.

Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas. We also deliver high-quality consumer and OTC THC-free CBD products that promote overall health and wellbeing as well as state-of-the-art testing and analytics capabilities to our customers. For more information, visit appliedbiocorp.com and connect with the Company on Twitter, Facebook and LinkedIn.

Applied BioSciences $APPB – New, Online Resource Designed to Assist Pharmacists With CBD Products $CGRW $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca

Posted by AGORACOM-Eric at 2:30 PM on Thursday, November 14th, 2019

SPONSOR: Applied Biosciences Corp. is a vertically integrated company focused on the development of science-driven cannabinoid therapeutics and biopharmaceuticals, as well as state-of-the-art testing and analytics. As a leading company in the CBD, Pet and Health and Wellness space, the company is currently shipping to the majority of US states as well as to 5 International countries. Click Here for More Info

The National Community Pharmacists Association (NCPA) has launched a new resource for pharmacists looking to understand and purchase reliable cannabidiol (CBD) products, called the NCPA CBD Source.

The online resource features CBD products that have been tested for concentrations of all cannabinoids, including CBD and tetrahydrocannabinol (THC), by an independent, third-party lab. The site also features experts that pharmacists can contact with questions regarding buying, selling, and marketing. In addition, pharmacists will be able to evaluate each company included in the resource, as well as see each company’s products.

CBD products have exploded in recent months following the Hemp Farming Act of 2018, which removed hemp from the list of Schedule I controlled substances. According to a statement from NCPA, the United States CBD industry grew by nearly 40% in 2017, and is expected to reach $22 billion by 2024.

CBD can help relieve pain and inflammation resulting from chronic illnesses, as well as boost the immune system, and these effects have led to a flood of patient interest.

“Many pharmacies are deciding to sell CBD products because of the patient demand and because, as the medication expert, they can serve as the source of truth,” said NCPA CEO B. Douglas Hoey, RPh, MBA.

Carter High, PharmD, of Best Value Rhome Pharmacy, said he plans on using the service to bolster the knowledge and products that he already trusts. CBD products are new to the pharmacy wheelhouse, High said, and he gets many phone calls with sales pitches from various CBD companies.

“It gets a little confusing as to whether or not they’re just talking a really good sales pitch, or if they really do have a genuine product,” High said.

High said it’s important for pharmacists to make sure they understand the uses and mechanisms of CBD products, but that this can be challenging given the crowded marketplace.

“Understanding just how CBD affects the body is a very good avenue for a pharmacist to delineate themselves as a knowledge expert on a new upcoming way of how to help patients out,” High said. “A marketplace such as [NCPA CBD Source] fills a very big gap that was missing, and helps from an efficiency standpoint at the store level.”

While he is excited to use the resources provided, High did emphasize that it doesn’t relieve pharmacists of the responsibility to ensure that the products are reliable, safe, and right for each patient. It does, however, help reassure pharmacists that the decisions they are making are the right ones, he added.

REFERENCE

NCPA, PRS Launch First-of-its-Kind “CBD Source” Tool for Pharmacists

https://www.ncpanet.org/newsroom/news-releases/2019/10/29/ncpa-prs-launch-first-of-its-kind-cbd-source-tool-for-pharmacists.

Applied BioSciences $APPB – CBD is ‘the caffeine of the 21st century’: Recess CEO $CGRW $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca

Posted by AGORACOM-Eric at 2:57 PM on Tuesday, November 5th, 2019

SPONSOR: Applied Biosciences Corp. is a vertically integrated company focused on the development of science-driven cannabinoid therapeutics and biopharmaceuticals, as well as state-of-the-art testing and analytics. As a leading company in the CBD, Pet and Health and Wellness space, the company is currently shipping to the majority of US states as well as to 5 International countries. Click Here for More Info

The key to selling a CBD product is to not sell the CBD, according to Benjamin Witte.

Witte is founder and CEO of Recess, a CBD and adaptogens-infused sparkling water brand based in New York. The one-year-old company has raised about $6 million in seed funding from as-yet undisclosed investors. Its pastel-hued 12-ounce cans are available in thousands of retail locations on the East Coast and in California.

As Witte sees it, the future of the CBD industry – and of Recess – will be about selling and marketing the feeling the component invokes, rather than the uber-trendy ingredient itself.

“The way to think about CBD is as a compound, no more interesting than caffeine or whey protein,” Witte said in an interview during Yahoo Finance’s monthly Breakouts series. “Just a commoditized functional ingredient that’s going to be added to many things.”

“I think the closest analogy to CBD is caffeine. I really believe it’s kind of the caffeine of the 21st century,” Witte added. “And, you know, what are the biggest caffeine companies? It’s Starbucks (SBUX), it’s Red Bull, et cetera. And they don’t market caffeine. They market the feeling that the compound enables, which kind of inspired our approach.”

Recess cans

‘Marketing a feeling’

CBD, officially known as cannabidiol, is expected to be a $16 billion market in the U.S. by 2025, according to a Cowen analysis earlier this year. CBD-infused beverages already comprise about one-fifth of the burgeoning market, although tinctures represent the most popular form for users. The substance has been touted for its potential to reduce pain and anxiety, although research to date remains inconclusive about its efficacy and proper dosing.

Looking at Recess’s sunset-colored packaging and slogans like “cool, calm, collected,” it’s clear CBD isn’t the focus. The company hardly promotes CBD at all, noting on its ingredient list it contains “10 mg of broad-spectrum hemp extract.” Witte refers to Recess as a “productivity company,” and said cans can be consumed as a less buzzy alternative to a morning cup of joe, afternoon pick-me-up or bedtime night cap.

The marketing strategy diverges from that of many of Recess’s competitors in a crowded CBD beverage space, many of which prominently promote the ingredient to capitalize on booming consumer interest in the substance. Upstarts from Mike Tyson’s The Ranch Company to public companies including New Age Beverage (NBEV) have launched CBD-infused beverages, many with similar dosages of the hemp-derived substance as Recess’ drinks.

It also underscores one potential route for steering public perception of the burgeoning industry, where a lack of clarity over the legality of the substance has capped growth and kept some retail partners on the sidelines.

While CBD is derived from cannabis, it by itself doesn’t get users high. The CBD in Recess is derived from hemp, which contains 0.3% or less of tetrahydrocannabinol (THC) and was removed from the Drug Enforcement Agency’s Schedule I classification as part of the Hemp Farm Bill in December 2018 (CBD can also be derived from marijuana, the plant that is typically more potent in psychoactive THC).

The Farm Bill moved oversight of the product to the Food and Drug Administration (FDA), which still considers CBD added to food products or marketed as a dietary supplement to be illegal at the federal level. But as Witte noted, the FDA has acknowledged the murky, asymmetrical rules governing CBD products at the state and federal levels.

“The FDA has actually kind of made statements saying … we recognize that this is uncertain, we recognize that the entire industry needs clarity, and that we’re effectively not going to enforce anyone besides the worst actors, people making claims around curing cancer and things like that,” Witte said.

To that end, “marketing a feeling” has been both a campaign strategy and, to an extent, means of keeping Recess out of the searchlight of regulators, which have clamped down on companies marketing CBD as a panacea for a host of medical ailments.

Startup beverage brand Dirty Lemon discontinued its CBD-infused beverage late last year just months after launching it, calling the endeavor “too much of a liability.” Public ventures including Curaleaf (CURLF), the most valuable U.S.-based cannabis company, have been recipients of warning letters from the FDA over making “unsubstantiated claims” that their products can treat cancer, Alzheimer’s disease, opioid withdrawal and other conditions.

Recess makes no such promises.

“We’re saying Recess is an antidote to modern times,” Witte said. “The idea is like, the world’s gone crazy, and we all need a Recess.”

Source: ttps://ca.finance.yahoo.com/news/cbd-is-the-caffeine-of-the-21st-century-recess-ceo-172920924.html

Applied BioSciences $APPB – Transparency in the CBD Sector $CGRW $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca

Posted by AGORACOM-Eric at 4:24 PM on Thursday, October 31st, 2019

SPONSOR: Applied Biosciences Corp. is a vertically integrated company focused on the development of science-driven cannabinoid therapeutics and biopharmaceuticals, as well as state-of-the-art testing and analytics. As a leading company in the CBD, Pet and Health and Wellness space, the company is currently shipping to the majority of US states as well as to 5 International countries. Click Here for More Info

Despite the tremendous growth of CBD in the pet space, many consumers are struggling to understand when, how or even if they should give CBD to their pets. For those who have made the decision to give CBD to their pets, there’s an increasing need to learn what’s actually in the CBD products they buy, including how much CBD is really in them.

Unfortunately, there’s not a lot of solid, accurate information out there for consumers to rely upon, and not every CBD product manufacturer makes finding product information easy for consumers. Therefore, retailers who sell CBD products or find themselves advising customers about CBD need to thoroughly investigate products before providing that advice. Additionally, those who sell CBD need to be able to reassure their customers about the CBD content of the products they supply.

In a recent television news interview on KRIS-TV, the NBC affiliate in Corpus Christi, Texas, veterinarian Dr. Wallace Graham said, “There are a lot of people getting in the business because it’s a way to make a lot of money quick because people are demanding it. My advice to people that ask me about using CBD and their pets is to buy it from a source that has a third-party or FDA analysis of their product. That needs to be an ongoing kind of thing so their products are tested from time to time so that it is established that they have in them what they say.” Graham also said that although the FDA doesn’t regulate CBD products, when they’re tested by the FDA, “Many of these products, they have found that they have little or no CBD in them, actually.”

Chelsea Rivera, head of content for HonestPaws.com, agrees. “Unfortunately, there are many unscrupulous companies that are not being upfront about the contents of their products,” she said. “For that reason, it is imperative that the buyer beware. From the start, we wanted to establish ourselves as an honest, transparent company that is on the side of the buyer. It’s even in our name.”

HonestPaws.com provides consumers with COA, or Certificate of Analysis, for their products right on their website. A COA is a document from an accredited laboratory that shows the quantity of various cannabinoids in a product. HonestPaws.com provides not only product information but COA for specific batches of products that have been sent to a lab for testing. Such laboratory analysis and certification is designed to protect customers and provide proof that each of the products have the amount of CBD in them that they advertise.

When asked why it is so important to HonestPaws.com to provide this information so readily to their customers, in addition to providing their customers peace of mind, Rivera said, “We hope to be an example in the CBD space to other companies. It’s hard for other companies to deny a consumer their COA when there are companies like Honest Paws who encourage their customers to ask for it.”